Arblet
2 known investors
Japanese health-data company operating Alysis, a platform that measures and analyzes vital signs and behavioral data.
Also known as Arblet Inc. · アーブレット · 株式会社Arblet
Founders & leadership
Investors · 2
Company profile
researched Aug 2026Arblet Inc. (株式会社Arblet) is a Tokyo-based company working on health and medical data technology, with a stated focus on blood pressure as a starting point for broader health insight. Its principal service, Alysis, is described as a platform that captures health data comprehensively by measuring and analyzing vital signs and behavioral data recorded in the course of daily life.
The company positions Alysis for two uses: supporting individual health management, and supplying findings that can be applied in medical research and clinical settings. Arblet holds a Class II medical device manufacturing and marketing licence (licence number 13B2X10478). The company explains its name as a combination of "Arm" (technology), "Orb" (something precious) and "Let" (to entrust), reflecting a stated mission of providing technology entrusted with people's lives.
Business model
Arblet develops and provides Alysis, a health-data measurement and analysis platform, serving both individual health management and medical research/clinical applications. The company operates under a Class II medical device manufacturing and marketing licence.
▸Full profile — technology, go-to-market, geography, history
Technology
Alysis performs precise measurement and analysis of vital signs and behavioral data generated in everyday life, with blood pressure identified as a central data point. The resulting analysis is intended both for personal health management and for generating insight usable in medical research and clinical practice.
Go-to-market
Individuals managing their own health, together with medical research organizations and clinical practitioners who can use the analyzed health data.
Geography
Head office in Ebisu-nishi, Shibuya-ku, Tokyo, Japan.
History
The company was established on 28 September 2016 and is headquartered in Ebisu-nishi, Shibuya-ku, Tokyo. Its stated capital is 100 million yen. Registered officers are Representative Director Kosuke Shimizu and Director Niki Agata.
Compiled by commissioned research from 4 cited public sources — announcements, filings, and press listed under research sources below.
Key figures
latest reportedCompany-reported or press-reported figures, each dated to when it was claimed — not independently audited.
Timeline · 1
launches, deals, and filingsArblet holds a Class II medical device manufacturing and marketing business licence, licence number 13B2X10478.
Dated company events from announcements, filings, and press; legal rows summarize public dockets and regulator releases.
▸Research sources · 4
primary sources listed
- Arblet Inc.arblet.com · web
4 public sources were cited for this profile; the first-party ones are listed here.
Frequently asked questions
- What does Arblet do?
- Japanese health-data company operating Alysis, a platform that measures and analyzes vital signs and behavioral data.
- Who founded Arblet?
- Arblet was founded by Kosuke Shimizu.
- Who are Arblet's investors?
- Arblet's investors include Colopl Next, Monozukuri Ventures.